Press releases

Press release2018/11/21

Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as a candidate drug (CD) for...

Press release2018/10/26

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

July – SeptemberSignificant events during the quarter Positive top-line joint structure outcomes were reported from the MIV-711 osteoarthritis phase II extension...

Press release2018/10/19

New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the initial phase II study of MIV-711,...

Press release2018/10/17

Medivir scales back research costs to focus on clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today plans to reduce activities not critical to its development pipeline of...

Press release2018/10/15

Medivir to focus on its clinical development and appoints Uli Hacksell as acting CEO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today its plans to concentrate its activities on clinical development. As a...

Press release2018/10/04

Positive interim data on birinapant in combination with Keytruda®

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced safety and efficacy data following an interim analysis of phase I...

Press release2018/10/01

Phase I/II clinical study of MIV-818 started in patients with liver cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and dosed with MIV-818...

Press release2018/09/10

Medivir appoints Dr. Linda Basse as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October...

Press release2018/08/02

Investigator-initiated phase II clinical study of remetinostat started in patients with basal cell carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient has been enrolled and is being dosed...

Press release2018/07/27

MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa...

Press release2018/07/25

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2018

April – JuneSignificant events during the quarter Positive top-line results from the MIV-711 osteoarthritis phase IIa extension study. The study met...

Press release2018/06/28

Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202)....